|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Cadence_Pharmaceuticals
gptkb:Questcor_Pharmaceuticals
Therakos
|
|
gptkbp:category
|
gptkb:insurance
conglomerate
life sciences company
company based in Dublin
company formerly based in Missouri
|
|
gptkbp:CEO
|
gptkb:Siggi_Olafsson
|
|
gptkbp:filedForBankruptcy
|
2020
2023
|
|
gptkbp:founded
|
1867
|
|
gptkbp:founder
|
gptkb:Gustav_Mallinckrodt
|
|
gptkbp:headquarters_location
|
gptkb:Dublin,_Ireland
|
|
gptkbp:headquartersLocation
|
gptkb:St._Louis,_Missouri,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mallinckrodt plc
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:involves
|
opioid litigation
|
|
gptkbp:ISIN
|
IE00BLL3CJ13
|
|
gptkbp:listedOn
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:notableProduct
|
gptkb:Acthar_Gel
gptkb:INOMAX
gptkb:Ofirmev
Therakos
|
|
gptkbp:numberOfEmployees
|
~3,400 (2023)
|
|
gptkbp:parentCompany
|
gptkb:Covidien
gptkb:Tyco_International
|
|
gptkbp:products
|
generic drugs
contrast media
specialty pharmaceuticals
|
|
gptkbp:revenue
|
$1.7 billion (2022)
|
|
gptkbp:settlement_amount
|
$1.6 billion (opioid litigation)
|
|
gptkbp:spinOff
|
gptkb:Covidien
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:MNK
|
|
gptkbp:website
|
https://www.mallinckrodt.com/
|
|
gptkbp:bfsParent
|
gptkb:Mallinckrodt_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|